Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Bellus Health Inc (NQ: BLU )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bellus Health Inc

< Previous 1 2 3 4 Next >
From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as... 
Via Benzinga
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
From BELLUS Health Inc.
Via Business Wire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
BELLUS Health: Q1 Earnings Insights
Via Benzinga
GSK Stock: A Value Trap or a Hidden Gem?
GSK, formerly known as GlaxoSmithKline, is struggling after a complicated earnings season. Here's why GSK stock is still a buy. 
Via InvestorPlace
BELLUS Health Inc. Calls Special Shareholders’ Meeting in Connection with GSK Acquisition
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
From BELLUS Health Inc.
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ruth’s Inc. (Nasdaq – RUTH), Magenta Therapeutics, Inc. (Nasdaq – MGTA), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX)
From Brodsky & Smith LLC
Via GlobeNewswire
Where BELLUS Health Stands With Analysts
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
BELLUS Health Announces Meeting Updates
From BELLUS Health Inc.
Via Business Wire
BELLUS Health Inc. (NASDAQ: BLU) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
3 Biotechs That Might Get Bought Out in 2023
Biotech is expected to be a hotbed of mergers and acquisitions this year. 
Via The Motley Fool
Was This Acquisition a Savvy Play by This Big Pharma Stock?
The British drugmaker picked up a potential blockbuster drug in its deal for Bellus Health. 
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE – UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
Second Quarter Outlook For Biotech Stocks
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. 
Via Talk Markets
Why This Nasdaq Stock Caught Fire This Week
A wave of bargain buying benefited the gene therapy company's shares this week. 
Via The Motley Fool
Why Shares of Bellus Health Skyrocketed This Week
The company has received a buyout offer from GSK. 
Via The Motley Fool
Dow Edges Higher; Goldman Sachs Posts Upbeat Earnings
U.S. stocks traded mixed toward the end of trading, with the Dow Jones turning higher on Tuesday. The Dow traded up 0.04% to 34,000.96 while the NASDAQ fell 0.13% to 12,141.79. The S&P 500, also rose,... 
Via Benzinga
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health
From BELLUS Health Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2023
Via Benzinga
Dow Dips Over 100 Points; Bank of America Earnings Beat Estimates
U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 100 points on Tuesday. The Dow traded down 0.42% to 33,842.93 while the NASDAQ fell 0.10% to 12,146.16. The S&P 500,... 
Via Benzinga
Why BELLUS Health Stock Is Rocketing Higher Today
A $2 billion buyout agreement with GSK is lighting a fire under the biotech's stock today. 
Via The Motley Fool
Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional... 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
Via Benzinga
US Stocks Mixed; Housing Starts Edge Lower In March
U.S. stocks traded mixed this morning, with the Nasdaq Composite dropping over 50 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.12% to 33,945.01 while the NASDAQ rose... 
Via Benzinga
Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion Deal
Shares of its takeover candidate nearly doubled on the news. 
Via Investor's Business Daily
Elon Musk Says US Intel Agencies Had Access To Twitter DMs, Alibaba's Ant IPO Might Actually See Light, Airbus Pushes Some 2024 Deliveries: Today's Top Stories
Benzinga Elon Musk Drops Bombshell: US Intel Agencies Were Reading Your Twitter DMs 
Via Benzinga
Why Is Gamida Cell (GMDA) Stock Up 48% Today?
Gamida Cell (GMDA) stock is taking off on Tuesday after getting an update from the FDA concerning cell therapy Omisirge. 
Via InvestorPlace
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.